How Do You Get on Ozempic for Weight Loss?

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Starting semaglutide for weight loss requires a medical evaluation and provider authorization, not a simple online request. Candidates typically have a BMI of 30 or higher, or 27+ with weight-related conditions, and must undergo metabolic and cardiovascular assessment before initiating therapy.

Many patients wonder whether they're appropriate candidates and what happens during evaluation. PlexusDx supports this decision-making by providing transparent clinical guidance and optional genetic context, helping patients prepare for meaningful conversations with their healthcare providers.

Medical Eligibility Criteria for Semaglutide Weight Loss

Medical eligibility for semaglutide extends beyond BMI alone. Providers assess baseline glucose metabolism, cardiovascular risk, kidney function, and history of thyroid or pancreatic disease. Pregnancy status and active gastrointestinal disorders also influence candidacy and dosing strategy.

Current clinical guidelines emphasize individualized assessment over blanket cutoffs. A BMI of 27+ with comorbidities like type 2 diabetes, hypertension, or sleep apnea may qualify, while some patients with BMI 30+ may have contraindications requiring alternative approaches.

The Provider Evaluation Process: What to Expect

A typical semaglutide evaluation includes medical history review, current medication inventory, physical examination, and baseline laboratory work. Labs often include fasting glucose, HbA1c, lipid panel, liver function tests, and kidney markers to establish metabolic baseline.

Evaluation Component	Purpose
Medical History	Identifies contraindications, prior GLP-1 use, and metabolic conditions
Cardiovascular Assessment	Evaluates baseline heart rate, blood pressure, and cardiac risk factors
Laboratory Baseline	Establishes glucose control, kidney function, and lipid status before treatment
Medication Review	Screens for interactions with semaglutide and diabetes medication adjustments
Lifestyle and Goals	Clarifies weight loss targets, dietary readiness, and injection adherence capacity
Thyroid and GI History	Identifies prior pancreatitis, medullary thyroid cancer, or thyroid nodules

Understanding Dosing Schedules and Treatment Timelines

Semaglutide treatment starts at a low dose and increases incrementally over 16–20 weeks to minimize gastrointestinal side effects and allow metabolic adjustment. Weekly subcutaneous injections begin at 0.25 mg, escalating by 0.25 mg increments until reaching a therapeutic dose of 2.0–2.4 mg.

Most patients experience appetite reduction and early weight change within 2–4 weeks, though meaningful metabolic benefits accumulate over 12–16 weeks. Providers monitor tolerance, weight trends, and metabolic markers monthly or quarterly, adjusting dose or frequency based on response and side effect profile.

Safety Considerations and Who Should Avoid Semaglutide

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, due to animal studies suggesting thyroid C-cell risk. Prior severe pancreatitis, gastroparesis, and certain kidney impairments also warrant caution or alternative therapy.

Common side effects include nausea, constipation, and vomiting, especially during dose escalation. Dehydration risk increases with GI symptoms, making fluid intake and provider communication essential. Patients on insulin or sulfonylureas require dose adjustments to prevent hypoglycemia when starting semaglutide.

Genetic Predispositions and Personalized Treatment Pathways

Genetic variations in GLP-1 receptor, GIPR, FTO, and MC4R genes influence how individuals metabolize appetite signals and respond to weight loss interventions. Understanding these predispositions may help providers tailor starting doses, escalation schedules, and combination approaches.

The PlexusDx Precision Peptide Genetic Test identifies predispositions in key peptide pathway variants, providing context for why some patients may experience robust responses while others require dose adjustments or alternative strategies. This genetic framework complements clinical assessment, supporting more informed provider conversations about treatment selection and personalization.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic insights may help provide context about individual predispositions in the GLP1R, GIPR, FTO, and MC4R pathways relevant to semaglutide response and appetite regulation. Genetic predispositions should be interpreted with a qualified healthcare provider alongside clinical evaluation, BMI, metabolic markers, and treatment history.

The Precision Peptide Genetic Test reveals predispositions in peptide-related genetic variants but does not predict exact semaglutide response or guarantee outcomes. Genetics is one factor among many; provider judgment, metabolic health, lifestyle capacity, and medication adherence remain central to treatment success.

When discussing semaglutide eligibility with your provider, sharing genetic predisposition results can support a more personalized conversation about starting dose, monitoring strategy, and whether combination peptide approaches might benefit your specific metabolic profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do I need a diabetes diagnosis to start semaglutide for weight loss?

No. Semaglutide is approved for weight management in patients without diabetes if BMI is 30+ or 27+ with weight-related conditions. Diabetes status does not determine eligibility, though glucose control is assessed during evaluation.

How long does the provider evaluation process take?

Initial evaluation typically takes 1–2 weeks from scheduling to first appointment. Lab results and provider review require 3–5 business days. First injection may occur within 1–3 weeks if all criteria are met.

Can I get semaglutide through PlexusDx?

PlexusDx offers compounded semaglutide injection ($149/mo) and oral semaglutide ($249/mo+) through licensed 503A pharmacies. All require active provider oversight and medical evaluation; compounded medications are not FDA-approved.

What if I have a history of pancreatitis or thyroid issues?

Prior pancreatitis is a relative contraindication requiring specialist clearance. Personal or family history of medullary thyroid cancer or MEN2 syndrome contraindicates semaglutide. Benign thyroid nodules require baseline ultrasound and monitoring during treatment.

How does the Precision Peptide Genetic Test help with semaglutide decisions?

The test reveals predispositions in GLP1R, GIPR, FTO, and MC4R variants that may provide context for individual appetite regulation patterns. This can support provider discussions about starting dose strategy and monitoring, though genetics does not predict exact medication response.